Ignite Creation Date:
2024-05-06 @ 8:10 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06289452
Status:
RECRUITING
Last Update Posted:
2024-05-07
First Post:
2024-02-25
Brief Title:
Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis
Sponsor:
InnoVec Biotherapeutics Inc
Organization:
InnoVec Biotherapeutics Inc
Study Overview
Official Title:
An Open-label Dose-escalation Clinical Study to Evaluate the Safety Tolerability and Preliminary Efficacy of IVB102 Injection in Subjects With X-linked Retinoschisis XLRS
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to evaluate the safety and efficacy of IVB102 injection in subjects with XLRS
Detailed Description:
This is a open label dose escalation single-center study One eye of each participant will receive a single IVB102 injection by intravitreal injection Participants will be followed for 52 weeks after which they will continue to be followed for up to 5 years after enrollment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None